-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Rebuilding Choice Architecture for Incurable but Treatable Lung Cancer: Rethinking the Future of Hospice Care in the United States
By Maggie Salinger, MD, MPP, and Arif Kamal, MD MBA, MHS, FAAHPM, FASCO Posted: December 11, 2019 IN REFERENCE TO: Mor V, Wagner TH, Levy C, et al. Association of expanded VA hospice care with aggressive care and cost for veterans with advanced lung cancer. JAMA Oncol. 2019 Jun 1;5(6):810-816. Dr. Maggie Salinger Hospice is…
-
A Balancing Act: Managing Patients’ Expectations
By Leah Lawrence Posted: December 11, 2019 Many patients newly diagnosed with lung cancer have difficulty navigating the world of cancer when unexpectedly and unwillingly thrust into it. In addition to understanding their diagnosis, prognosis, and treatment options, patients are also bombarded with an abundance of information on the internet, direct-to-consumer advertising of new cancer…
-
PD-L1 in Cytology Specimens
By Anjali Saqi, MD, MBA; Deepali Jain, MD, FIAC; Lukas Bubendorf, MD; Keith Kerr, MB, ChB, MRCPath, FRCPath, FRCP(Ed); and Andre Moreira, MD, PhD Posted: December 11, 2019 Lung cancer is a leading cause of cancer-related deaths worldwide. In the 21st century, there have been two significant developments in the systemic management of lung cancers.…
-
STARS Patient Research Advocate Training Program Seeks Patients and Caregivers
By Adam Mohrbacher Posted: December 11, 2019 Patients with lung cancer and their caregivers are becoming more empowered and knowledgeable than ever. As a result, lung cancer now has a growing group of patients who have lived long enough to become advocates for their disease. Some are evolving into research advocates— volunteers with a personal…
-
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab
By Suresh Ramalingam, MD Posted: December 11, 2019 IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non–Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518-2527. Immune checkpoint inhibition is now part of routine care for patients with…
-
From Patient to Patient Research Advocate: The STARS Journey
By Adam Mohrbacher Posted: December 11, 2019 With the rise of organized lung cancer patient advocacy groups,1 patients, advocates, and caregivers are now playing a larger role than ever in raising awareness, providing education, and even driving research into the disease. In order to support this groundswell of passion and advocacy, the IASLC’s Supportive Training…
-
Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies
By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a single disease: HER2 gene amplification with breast cancer, BCR-ABL fusions with chronic myelogenous leukemia, EGFR mutations with lung cancer, and BRAF mutations with melanoma. Thus,…
-
First-Ever IASLC School of Nursing Held at Latin American Lung Cancer Regional Meeting in Mexico City
By Enza Esposito Nguyen, DNP Posted: December 11, 2019 Dr. Enza Esposito Nguyen The IASLC held its ninth Latin American Lung Cancer (LALCA) regional meeting in Mexico City this past October. Interest in this meeting has grown consistently, with more than 800 attendees participating this year. Each year, pre-conference schools are offered to provide in-depth…
-
Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC
By Christian Rolfo, MD, PhD, MBA, Dr.h.c. Posted: December 11, 2019 IN REFERENCE TO: Phallen J, Leal A, Woodward BD, et al. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2019;79(6):1204-1213. Anagnostou V, Forde PM, White JR, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint…
-
Highlights From the 2019 IASLC Latin American Conference in Lung Cancer
By Luis E. Raez, MD, FACP, FCCP Posted: December 11, 2019 The 8th IASLC Latin American Conference in Lung Cancer (LALCA) was held in Mexico City, Mexico, from October 18 to 20, 2019. The LALCA is the main event of the IASLC Latin American Group (LATAM), which has close to 500 members in almost 20…
View ILCN Archives
Provider Resources
Popular Articles